These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 36507589

  • 1. Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
    Sharma P, Singh N, Sharma S.
    J Biochem Mol Toxicol; 2023 Mar; 37(3):e23269. PubMed ID: 36507589
    [Abstract] [Full Text] [Related]

  • 2. Impact of ABCB1, ABCC1, ABCC2, and ABCG2 variants in predicting prognosis and clinical outcomes of north Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
    Sharma P, Singh N, Sharma S.
    J Gene Med; 2023 Jan; 25(1):e3460. PubMed ID: 36314103
    [Abstract] [Full Text] [Related]

  • 3. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
    Qian CY, Zheng Y, Wang Y, Chen J, Liu JY, Zhou HH, Yin JY, Liu ZQ.
    Chin J Cancer; 2016 Sep 02; 35(1):85. PubMed ID: 27590272
    [Abstract] [Full Text] [Related]

  • 4. ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.
    De Troia B, Dalu D, Filipazzi V, Isabella L, Tosca N, Ferrario S, Gambaro AR, Somma L, Fasola C, Cheli S, Clementi E, De Francesco D, Falvella FS, Cattaneo MT.
    Cancer Chemother Pharmacol; 2019 Apr 02; 83(4):803-808. PubMed ID: 30796464
    [Abstract] [Full Text] [Related]

  • 5. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
    Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H, DeLoia JA.
    Gynecol Oncol; 2012 Mar 02; 124(3):575-81. PubMed ID: 22112610
    [Abstract] [Full Text] [Related]

  • 6. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS.
    Cancer; 2007 Jul 01; 110(1):138-47. PubMed ID: 17534875
    [Abstract] [Full Text] [Related]

  • 7. Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
    Kim SH, Kim MJ, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim IS, Lee S, Oh SY, Ling H, Lee GW.
    Am J Clin Oncol; 2015 Jun 01; 38(3):294-9. PubMed ID: 23689644
    [Abstract] [Full Text] [Related]

  • 8. Genetic Variants in the Wingless Antagonist Genes (sFRP, DKK, and Axin2) Predict the Overall Survival and Prognosis of North Indian Lung Cancer Patients Treated with Platinum-Based Doublet Chemotherapy.
    Bahl C, Singh N, Behera D, Sharma S.
    Cancer Biother Radiopharm; 2018 Dec 01; 33(10):466-477. PubMed ID: 30346805
    [Abstract] [Full Text] [Related]

  • 9. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
    Tamura M, Kondo M, Horio M, Ando M, Saito H, Yamamoto M, Horio Y, Hasegawa Y.
    Nagoya J Med Sci; 2012 Feb 01; 74(1-2):133-40. PubMed ID: 22515119
    [Abstract] [Full Text] [Related]

  • 10. Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
    Anai S, Iwama E, Yoneshima Y, Otsubo K, Tanaka K, Nakanishi Y, Okamoto I.
    Lung Cancer; 2018 Dec 01; 126():156-161. PubMed ID: 30527181
    [Abstract] [Full Text] [Related]

  • 11. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
    Akasaka K, Kaburagi T, Yasuda S, Ohmori K, Abe K, Sagara H, Ueda Y, Nagao K, Imura J, Imai Y.
    Cancer Chemother Pharmacol; 2010 Sep 01; 66(4):691-8. PubMed ID: 20035425
    [Abstract] [Full Text] [Related]

  • 12. XPG polymorphisms and their association with lung cancer susceptibility, overall survival and response in North Indian patients treated with platinum-based doublet chemotherapy.
    Lawania S, Singh N, Behera D, Sharma S.
    Future Oncol; 2019 Jan 01; 15(2):151-165. PubMed ID: 30522358
    [Abstract] [Full Text] [Related]

  • 13. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
    Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR.
    J Clin Oncol; 2009 May 20; 27(15):2530-5. PubMed ID: 19349543
    [Abstract] [Full Text] [Related]

  • 14. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
    Pérez-Ramírez C, Cañadas-Garre M, Alnatsha A, Villar E, Delgado JR, Faus-Dáder MJ, Calleja-Hernández MŸ.
    Pharmacol Res; 2016 Sep 20; 111():877-884. PubMed ID: 27498158
    [Abstract] [Full Text] [Related]

  • 15. Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
    Lemos C, Giovannetti E, Zucali PA, Assaraf YG, Scheffer GL, van der Straaten T, D'Incecco A, Falcone A, Guchelaar HJ, Danesi R, Santoro A, Giaccone G, Tibaldi C, Peters GJ.
    Pharmacogenomics; 2011 Feb 20; 12(2):159-70. PubMed ID: 21332310
    [Abstract] [Full Text] [Related]

  • 16. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
    Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J.
    J Thorac Oncol; 2014 May 20; 9(5):702-9. PubMed ID: 24662458
    [Abstract] [Full Text] [Related]

  • 17. Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
    Kanda S, Ohe Y, Goto Y, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Yamamoto T, Tamura T.
    Cancer Sci; 2020 Jun 20; 111(6):1933-1942. PubMed ID: 32277531
    [Abstract] [Full Text] [Related]

  • 18. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
    Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, Schellens JH.
    Cancer; 2012 May 01; 118(9):2466-75. PubMed ID: 22031394
    [Abstract] [Full Text] [Related]

  • 19. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S.
    J Clin Oncol; 2016 Sep 01; 34(25):2969-79. PubMed ID: 27354481
    [Abstract] [Full Text] [Related]

  • 20. UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
    Bandyopadhyay A, Sharma S, Behera D, Singh N.
    Oncologist; 2021 Aug 01; 26(8):701-713. PubMed ID: 33728696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.